249 related articles for article (PubMed ID: 11992180)
21. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis.
Krueger GG; Drake LA; Elias PM; Lowe NJ; Guzzo C; Weinstein GD; Lew-Kaya DA; Lue JC; Sefton J; Chandraratna RA
Arch Dermatol; 1998 Jan; 134(1):57-60. PubMed ID: 9449910
[TBL] [Abstract][Full Text] [Related]
22. A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy.
Kaidbey K; Kopper SC; Sefton J; Gibson JR
Int J Dermatol; 2001 Jul; 40(7):468-71. PubMed ID: 11679006
[TBL] [Abstract][Full Text] [Related]
23. Tazarotene in combination with phototherapy.
Koo JY
J Am Acad Dermatol; 1998 Oct; 39(4 Pt 2):S144-8. PubMed ID: 9777793
[TBL] [Abstract][Full Text] [Related]
24. Tazarotene combination treatments in psoriasis.
Guenther L
J Am Acad Dermatol; 2000 Aug; 43(2 Pt 3):S36-42. PubMed ID: 10898828
[TBL] [Abstract][Full Text] [Related]
25. Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris.
Queille-Roussel C; Nielsen J; Lacour JP
J Dermatolog Treat; 2019 Sep; 30(6):529-533. PubMed ID: 30582717
[No Abstract] [Full Text] [Related]
26. An observation study evaluating the efficacy of tazarotene plus corticosteroid in treating plaque psoriasis in patients switched from treatment with calcipotriene +/- corticosteroid.
Tanghetti EA;
Cutis; 2000 Dec; 66(6 Suppl):12-8. PubMed ID: 11147086
[TBL] [Abstract][Full Text] [Related]
27. Comparative efficacy of once-daily flurandrenolide tape versus twice-daily diflorasone diacetate ointment in the treatment of psoriasis.
Krueger GG; O'Reilly MA; Weidner M; Dromgoole SH; Killey FP
J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):186-90. PubMed ID: 9486672
[TBL] [Abstract][Full Text] [Related]
28. Mometasone furoate 0.1%-salicylic acid 5% ointment twice daily versus fluocinonide 0.05% ointment twice daily in the management of patients with psoriasis.
Medansky RS; Cuffie CA; Tanner DJ
Clin Ther; 1997; 19(4):701-9. PubMed ID: 9377614
[TBL] [Abstract][Full Text] [Related]
29. Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments.
Lebwohl M; Lombardi K; Tan MH
Int J Dermatol; 2001 Jan; 40(1):64-6. PubMed ID: 11277960
[No Abstract] [Full Text] [Related]
30. Tazarotene.
Foster RH; Brogden RN; Benfield P
Drugs; 1998 May; 55(5):705-11; discussion 712. PubMed ID: 9585866
[TBL] [Abstract][Full Text] [Related]
31. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
Weinstein GD; Koo JY; Krueger GG; Lebwohl MG; Lowe NJ; Menter MA; Lew-Kaya DA; Sefton J; Gibson JR; Walker PS;
J Am Acad Dermatol; 2003 May; 48(5):760-7. PubMed ID: 12734506
[TBL] [Abstract][Full Text] [Related]
32. Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent.
Medansky RS; Bressinck R; Cole GW; Deeken JH; Ellis CN; Guin JD; Herndon JH; Lasser AE; Leibsohn E; Menter MA
Cutis; 1988 Nov; 42(5):480-5. PubMed ID: 3058398
[TBL] [Abstract][Full Text] [Related]
33. A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis.
Tzaneva S; Hönigsmann H; Tanew A; Seeber A
Br J Dermatol; 2002 Oct; 147(4):748-53. PubMed ID: 12366423
[TBL] [Abstract][Full Text] [Related]
34. Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis.
Tzung TY; Wu JC; Hsu NJ; Chen YH; Ger LP
Acta Derm Venereol; 2005; 85(3):236-9. PubMed ID: 16040409
[TBL] [Abstract][Full Text] [Related]
35. Instrumental evaluation of retinoid-induced skin irritation.
Stücker M; Hoffmann M; Altmeyer P
Skin Res Technol; 2002 May; 8(2):133-40. PubMed ID: 12060479
[TBL] [Abstract][Full Text] [Related]
36. Comparison of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of psoriasis.
Roberts DT
Cutis; 1996 Feb; 57(2 Suppl):27-31. PubMed ID: 8646866
[TBL] [Abstract][Full Text] [Related]
37. Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy.
Tanghetti E; Lebwohl M; Stein Gold L
J Drugs Dermatol; 2018 Dec; 17(12):1280-1287. PubMed ID: 30586259
[TBL] [Abstract][Full Text] [Related]
38. Tazarotene gel: efficacy and safety in plaque psoriasis.
Weinstein GD
J Am Acad Dermatol; 1997 Aug; 37(2 Pt 3):S33-8. PubMed ID: 9270554
[TBL] [Abstract][Full Text] [Related]
39. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
[TBL] [Abstract][Full Text] [Related]
40. Efficacy, safety, and cost-effectiveness of all-trans retinoic acid/Clobetasol Propionate Compound Ointment in the treatment of mild to moderate psoriasis vulgaris: A randomized, single-blind, multicenter clinical trial.
Xia L; Li R; Wang Y; Lin Z; Zheng J; Li X; Lu Q; Zhang J; Jin H; Fu L; Zhang X; Liu Y; Yang S; Xiao F; Gao XH
Dermatol Ther; 2018 Sep; 31(5):e12632. PubMed ID: 30253049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
